Intercept Pharmaceuticals Inc

ICPT

$20.84

-74.2% (1 year change)

Avg closing price

Price range

Market Cap

$671 Million

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$13.88 - $83.57

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

-3.02x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $671 Million
Enterprise Value $828 Million
Dividend Yield $0.00 (0.0%)
1 Year Return -74.2%
52-Week High $83.57
52-Week Low $13.88
Beta 0.75
Outstanding Shares 33.2 Million
Avg 30 Day Volume 1.05 Million

Valuation

P/E Ratio -3.02
PEG 5.34
Earnings per Share -$6.71
Price to Sales Ratio 2.32
Price to Book Ratio -2.98
Revenue to Enterprise Value 2.57
EBIT to Enterprise Value -5.1
Total Debt to Enterprise Value 0.69
Debt to Equity -2.84

Profitability

Revenue $322 Million
Gross Profit $316 Million
EBIT -$162 Million
Net Income -$222 Million
Profit Margin -69.11%
Quarterly Earnings Growth (YoY) -56.5%
Return on Equity 111.16%
Return on Assets -42.74%
Return on Invested Capital -43.42%

News

HighTide Therapeutics Appoints Dr. Leigh MacConell as Chief Development Officer

HighTide Therapeutics Appoints Dr. Leigh MacConell as Chief Development Officer

SHENZHEN, China & ROCKVILLE, Md.--(BUSINESS WIRE)--HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced the appointment of Leigh MacConell, Ph.D., as...

Business Wire Business Wire, 5 months ago
Intercept to Present at the 39th Annual J.P. Morgan Healthcare Conference

Intercept to Present at the 39th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and…

GlobeNewswire GlobeNewswire, 6 months ago
ICPT Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Intercept Pharmaceuticals, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: January 4, 2021 | MarketScreener

ICPT Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Intercept Pharmaceuticals, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: January 4, 2021 | MarketScreener

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc. and certain of its officers, on behalf of shareholders… | Ja...

MarketScreener MarketScreener, 6 months ago